The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.
US physicians can now remotely adjust the programming of an Abbott neuromodulation device using the company's new NeuroSphere Virtual Clinic system.
On 8 March, the company announced the US Food and Drug Administration approval and commercial launch of its Virtual Clinic system. According to Abbott, it is the first technology to...
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
